ATLANTA--(BUSINESS WIRE)--Inhibitex, Inc. (NASDAQ: INHX) announced today that a poster presentation detailing preclinical data from its HCV nucleoside polymerase inhibitor program will be presented by Dr. John Vernachio, vice president of biology, at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) in Copenhagen, Denmark on Saturday, April 25th. The full abstract can be viewed at the EASL website at www.easl.ch.
